Glass K, Fines C, Coulter P, Jena L, McCarthy H, Buckley N
Mol Pharm. 2024; 21(10):4970-4982.
PMID: 39196792
PMC: 11462496.
DOI: 10.1021/acs.molpharmaceut.4c00299.
Clements M, Holtslander L, Johnson J, Johnson R
JBMR Plus. 2023; 7(3):e10694.
PMID: 36936362
PMC: 10020917.
DOI: 10.1002/jbm4.10694.
Peng R, Liang X, Zhang G, Yao Y, Chen Z, Pan X
Biomed Res Int. 2020; 2020:5606573.
PMID: 33102580
PMC: 7568169.
DOI: 10.1155/2020/5606573.
Gschwantler-Kaulich D, Weingartshofer S, Grunt T, Mairhofer M, Tan Y, Gamper J
PLoS One. 2017; 12(9):e0185566.
PMID: 28945801
PMC: 5612728.
DOI: 10.1371/journal.pone.0185566.
Fragni M, Bonini S, Bettinsoli P, Bodei S, Generali D, Bottini A
Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(5):529-38.
PMID: 26905520
DOI: 10.1007/s00210-016-1224-8.
Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.
Biray Avci C, Caliskan Kurt C, Tepedelen B, Ozalp O, Goker B, Mutlu Z
Tumour Biol. 2015; 37(5):6673-9.
PMID: 26646564
DOI: 10.1007/s13277-015-4519-3.
Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model.
Chung Y, Kang H, Lee T
Yonsei Med J. 2015; 56(6):1643-50.
PMID: 26446649
PMC: 4630055.
DOI: 10.3349/ymj.2015.56.6.1643.
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Hue T, Cummings S, Cauley J, Bauer D, Ensrud K, Barrett-Connor E
JAMA Intern Med. 2014; 174(10):1550-7.
PMID: 25111880
PMC: 4398333.
DOI: 10.1001/jamainternmed.2014.3634.
A new bisphosphonate derivative, CP, induces gastric cancer cell apoptosis via activation of the ERK1/2 signaling pathway.
Wang H, Liu Y, Fan L, Han C, Jiang Y, Cheng S
Acta Pharmacol Sin. 2013; 34(12):1535-44.
PMID: 24241351
PMC: 4002562.
DOI: 10.1038/aps.2013.103.
Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.
Schech A, Kazi A, Gilani R, Brodie A
Mol Cancer Ther. 2013; 12(7):1356-66.
PMID: 23619300
PMC: 3711266.
DOI: 10.1158/1535-7163.MCT-12-0304.
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
Valachis A, Polyzos N, Coleman R, Gnant M, Eidtmann H, Brufsky A
Oncologist. 2013; 18(4):353-61.
PMID: 23404816
PMC: 3639520.
DOI: 10.1634/theoncologist.2012-0261.
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
Fehm T, Zwirner M, Wallwiener D, Seeger H, Neubauer H
BMC Cancer. 2012; 12:308.
PMID: 22824103
PMC: 3416722.
DOI: 10.1186/1471-2407-12-308.
Zoledronic acid inhibits aromatase activity and phosphorylation: potential mechanism for additive zoledronic acid and letrozole drug interaction.
Schech A, Nemieboka B, Brodie A
J Steroid Biochem Mol Biol. 2012; 132(3-5):195-202.
PMID: 22659283
PMC: 3463743.
DOI: 10.1016/j.jsbmb.2012.05.008.
Direct antitumour activity of zoledronic acid: preclinical and clinical data.
Bosch-Barrera J, Merajver S, Menendez J, Van Poznak C
Clin Transl Oncol. 2011; 13(3):148-55.
PMID: 21421459
DOI: 10.1007/s12094-011-0634-9.
Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers.
Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller T, Scheper M
J Carcinog. 2011; 10:2.
PMID: 21297922
PMC: 3030761.
DOI: 10.4103/1477-3163.75723.
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.
Brown H, Ottewell P, Coleman R, Holen I
J Cell Mol Med. 2009; 15(3):501-13.
PMID: 20015195
PMC: 3922372.
DOI: 10.1111/j.1582-4934.2009.00995.x.
Zoledronic acid: a review of its use in breast cancer.
Lyseng-Williamson K
Drugs. 2008; 68(18):2661-82.
PMID: 19093706
DOI: 10.2165/0003495-200868180-00010.
Hormesis and medicine.
Calabrese E
Br J Clin Pharmacol. 2008; 66(5):594-617.
PMID: 18662293
PMC: 2661975.
DOI: 10.1111/j.1365-2125.2008.03243.x.
Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors.
Brufsky A
Curr Oncol Rep. 2008; 10(1):18-26.
PMID: 18366957
DOI: 10.1007/s11912-008-0005-z.